肾母细胞瘤患儿p73基因的表达及其甲基化研究

宋东建; 岳丽芳; 张大; 杨合英; 樊玉霞; 岳铭; 裴航; 王家祥

doi:10.7499/j.issn.1008-8830.2013.08.009

PDF(915 KB)

中国当代儿科杂志 ›› 2013, Vol. 15 ›› Issue (8) : 638-643. DOI: 10.7499/j.issn.1008-8830.2013.08.009

论著·临床研究

肾母细胞瘤患儿p73基因的表达及其甲基化研究

宋东建，岳丽芳，张大，杨合英，樊玉霞，岳铭，裴航，王家祥

作者信息 +

Relationship between mRNA expression and promoter methylation status of p73 gene in peripheral blood among children with Wilms' tumor

SONG Dong-Jian, YUE Li-Fang, ZHANG Da, YANG He-Ying, FAN Yu-Xia, YUE Ming, PEI Hang, WANG Jia-Xiang

Author information +

文章历史 +

摘要

目的：探讨肾母细胞瘤患儿血液中p73基因的转录表达、启动子甲基化状态及二者之间关系。方法：收集45例肾母细胞瘤患儿为病例组，以健康体检或因其他原因就诊的性别、年龄匹配的15例（排除肿瘤等恶性疾病）儿童为对照组。采集两组儿童外周血，运用实时荧光定量PCR（qRT-PCR）和甲基化特异性PCR (MSP)法检测p73基因转录表达水平及其启动子甲基化状态，并分析病例组中p73基因的表达及甲基化与临床资料的关系，及p73基因的甲基化对其转录表达的影响。结果：病例组中p73 mRNA的相对表达量（3.2±0.9）高于对照组（1.6±1.1），差异有统计学意义（P<0.01）；病例组p73基因甲基化阳性率（20%）低于对照组 (73%)，差异有统计学意义（P<0.01）。病例组中甲基化p73 mRNA的相对表达量大于非甲基化p73 mRNA的相对表达量（P<0.01），且大于对照组中甲基化p73 mRNA的相对表达量（P<0.01）；非甲基化p73 mRNA的相对表达量在两组间差异无统计学意义（P=0.810）。结论：肾母细胞瘤外周血中p73基因启动子的异常甲基化是其基因表达调节方式之一，并与肾母细胞瘤的发生发展有关；发生甲基化的p73基因在肾母细胞瘤中有可能充当癌基因的角色，转录水平的过度表达与其甲基化状态有关。

Abstract

OBJECTIVE: To investigate the mRNA expression and promoter methylation status of p73 gene in the peripheral blood of children with Wilms' tumor (WT), and their relationship. METHODS: Forty-five children with WT were selected as the case group, and 15 sex- and age- matched children (without malignancies) who visited the hospital for physical examination or other reasons were selected as the control group. Peripheral blood was collected from both groups. Real-time quantitative PCR and methylation-specific PCR were used to determine the mRNA expression level and promoter methylation status of p73 gene. Their relationship with clinicopathological features and the effect of promoter methylation on mRNA expression of p73 gene were analyzed in the case group. RESULTS: The relative quantity (RQ) of p73 mRNA in the case group was significantly higher than in the control group (3.2±0.9 vs 1.6±1.1; P<0.01). The positive rate of p73 gene promoter methylation in the case group was significantly lower than in the control group (20% vs 73%; P<0.01). In the case group, the RQ of p73 mRNA was significantly higher in children with methylated p73 gene promoter than in those with unmethylated p73 gene promoter (P<0.01). In children with methylated p73 gene promoter, the RQ of p73 mRNA was significantly higher in the case group than in the control group (P<0.01). In children with unmethylated p73 gene promoter, there was no significant difference in RQ of p73 mRNA between the case and control groups (P=0.810). CONCLUSIONS: Aberrant promoter methylation of p73 gene in peripheral blood is one of the gene expression regulations in children with WT, and it is related to the onset and development of WT. The p73 gene may play a role as oncogene in WT patients with p73 gene promoter methylation and mRNA overexpression is associated with promoter methylation status of p73 gene.

导出引用

宋东建，岳丽芳，张大，杨合英，樊玉霞，岳铭，裴航，王家祥. 肾母细胞瘤患儿p73基因的表达及其甲基化研究[J]. 中国当代儿科杂志. 2013, 15(8): 638-643 https://doi.org/10.7499/j.issn.1008-8830.2013.08.009

SONG Dong-Jian, YUE Li-Fang, ZHANG Da, YANG He-Ying, FAN Yu-Xia, YUE Ming, PEI Hang, WANG Jia-Xiang. Relationship between mRNA expression and promoter methylation status of p73 gene in peripheral blood among children with Wilms' tumor[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(8): 638-643 https://doi.org/10.7499/j.issn.1008-8830.2013.08.009

参考文献

[1] 王先火, 赵秀娟, 邱立华, 王华庆, 王玺. 肿瘤发生的表观遗传学：进展与临床意义[J].北京大学学报, 2012, 5(8): 701-707.

[2] Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, et al. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor[J]. J Pediatr Surg, 2012, 47(6): 1239-1249.

[3] Jha AK, Nikbakht M, Jain V, Sehgal A, Capalash N, Kaur J. Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population[J]. Mol Biol Rep, 2012, 39(9): 9145-9157.

[4] Marabese M，Vikhanskaya F, Broggini M. p73: a chiaroscuro gene in cancer[J]. Eur J Cancer, 2007, 43(9): 1361-1372.

[5] Gonzalez-Cano L, Herreros-Villanueva M, Fernandez-Alonso R, Ayuso-Sacido A, Meyer G, Garcia-Verdugo JM, et al. p73 deficiency results in impaired self renewal and premature neuronal differentiation of mouse neural progenitors independently of p53 [J]. Cell Death Dis, 2010, 1: e109.

[6] Ye B, Wang X, Yang Z, Sun Z, Zhang R, Hu Y, et al. p53 and p73 expression in esophageal carcinoma correlate with clinicopathology of tumors[J]. Hepatogastroenterology, 2012, 59(119): 2192-2195.

[7] Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W,et al. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems[J]. Diaqn Pathol, 2012, 7: 120.

[8] Moll UM, Slade N. p63 and p73: roles in development and tumor formation[J]. Mol Cancer Res, 2004, 2(7): 371-386.

[9] Niemantsverdriet M, Nagle P, Chiu RK, Langendijk JA, Kampinga HH, Coppes RP. ΔNp73 Enhances Promoter Activity of TGF-β Induced Genes[J]. PLoS One, 2012, 7(12): e50815.

[10] Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, et al. DeltaN-p73 alpha accumulates in human neuroblastic tumours[J] . Am J Pathol, 2002, 160(2): 631-639.

[11] Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73[J]. Cancer Res, 2002, 62(3): 636-641.

[12] Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, et al. Transdominant ΔTAp73 isoforms are frequently up-regulated in Ovarian Cancer.Evidence for their role as epigenetic p53 inhibitors in vivo[J]. Cancer Res, 2004, 64(7): 2449-2460.

[13] McKeon F, Melino G. Fog of war: the emerging p53 family[J]. Cell Cycle, 2007, 6(3): 229-232.

[14] Ozono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, et al. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts[J]. Genes Cells, 2012, 17(8): 660-672.

[15] Melino G, Laurenzi VD, Vousden KH. p73: friend or foe in tumorigenesis[J]. Nat Rev Cancer, 2002, 2(8): 605-615.

[16] Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW, Hu WX. The association between non-Hodgkin lymphoma and methylation of p73[J]. Tumor Bio, 2011, 32(6): 1133-1138.

[17] 张妍, 高宇, 王筱金, 朱莎, 施蓉, 金萍, 等. p73基因DNA甲基化与儿童急性白血病的关系[J]. 上海交通大学报, 2011, 7(16): 942-946.

[18] Abd El-Hamid TM, Mossallam GI, Sherisher MA. The Clinical Implications of Methylated p15 and p73 Genes in Adult Acute Lymphoblastic Leukemia[J]. J Egypt Natl Canc Inst, 2010, 22(3): 175-184.

[19] Saito M, Nishikawa J, Okada T, Morishige A, Sakai K, Nakamura M, et al. Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma[J]. J Med Virol, 2013, 85(1): 121-127.

[20] Zhao Y, Fei C, Zhang X, Zhang Y, Guo J, Gu S, et al. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis[J]. Tumor Biol, 2013, 34(1): 165-172.

[21] Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN, et al. Global DNA hypomethylation-induced △Np73 transcriptional activation in non-small cell lung cancer[J]. Cancer Lett, 2011, 300(1): 79-86.